Pharmacokinetic study of metopimazine by oral route in children.
Identifieur interne : 000080 ( PubMed/Checkpoint ); précédent : 000079; suivant : 000081Pharmacokinetic study of metopimazine by oral route in children.
Auteurs : Eric Mallet [France] ; Frederic Bounoure [France] ; Mohamed Skiba [France] ; Elodie Saussereau [France] ; Jean-Pierre Goullé [France] ; Mireille Castanet [France]Source :
- Pharmacology research & perspectives ; 2015.
Abstract
Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In France, it has become the leading antiemetic mediator due to its good tolerance, however, its pharmacokinetics has never previously been studied in children. MPZ was administered by oral route to 8 children with a single dose of 0.33 mg/kg during an endocrine exploration using stimuli well known for its adverse emetic effects. We used biological remnants from sera following an hGH test in order to obtain the MPZ pharmacokinetics. Plasmatic concentrations of MPZ and the active acid metabolite AMPZ, were quantified by HPLC-MS/MS during a 270 min test period. MPZ is quickly absorbed with a median C max of 17.2 ng/mL at one hour and its half-life is 2.18 h. The plasmatic concentrations of AMPZ were higher than MPZ with a median C max of 76.3 ng/mL, a T max to 150 min and its concentration was approximately maintained at 50 ng/mL from 1 to 4 h. The plasmatic concentrations in children are similar to those observed in adults. No adverse effects, nausea or vomiting occurred during the trial. Therefore, these results confirm the MPZ dosage that should be used in children under 15 kg administered as 0.33 mg/kg up to 3 times a day.
DOI: 10.1002/prp2.130
PubMed: 26171218
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26171218Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetic study of metopimazine by oral route in children.</title><author><name sortKey="Mallet, Eric" sort="Mallet, Eric" uniqKey="Mallet E" first="Eric" last="Mallet">Eric Mallet</name><affiliation wicri:level="3"><nlm:affiliation>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Bounoure, Frederic" sort="Bounoure, Frederic" uniqKey="Bounoure F" first="Frederic" last="Bounoure">Frederic Bounoure</name><affiliation wicri:level="3"><nlm:affiliation>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Skiba, Mohamed" sort="Skiba, Mohamed" uniqKey="Skiba M" first="Mohamed" last="Skiba">Mohamed Skiba</name><affiliation wicri:level="3"><nlm:affiliation>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Saussereau, Elodie" sort="Saussereau, Elodie" uniqKey="Saussereau E" first="Elodie" last="Saussereau">Elodie Saussereau</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Le Havre</settlement></placeName></affiliation></author><author><name sortKey="Goulle, Jean Pierre" sort="Goulle, Jean Pierre" uniqKey="Goulle J" first="Jean-Pierre" last="Goullé">Jean-Pierre Goullé</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Le Havre</settlement></placeName></affiliation></author><author><name sortKey="Castanet, Mireille" sort="Castanet, Mireille" uniqKey="Castanet M" first="Mireille" last="Castanet">Mireille Castanet</name><affiliation wicri:level="3"><nlm:affiliation>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26171218</idno><idno type="pmid">26171218</idno><idno type="doi">10.1002/prp2.130</idno><idno type="wicri:Area/PubMed/Corpus">000089</idno><idno type="wicri:Area/PubMed/Curation">000089</idno><idno type="wicri:Area/PubMed/Checkpoint">000089</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetic study of metopimazine by oral route in children.</title><author><name sortKey="Mallet, Eric" sort="Mallet, Eric" uniqKey="Mallet E" first="Eric" last="Mallet">Eric Mallet</name><affiliation wicri:level="3"><nlm:affiliation>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Bounoure, Frederic" sort="Bounoure, Frederic" uniqKey="Bounoure F" first="Frederic" last="Bounoure">Frederic Bounoure</name><affiliation wicri:level="3"><nlm:affiliation>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Skiba, Mohamed" sort="Skiba, Mohamed" uniqKey="Skiba M" first="Mohamed" last="Skiba">Mohamed Skiba</name><affiliation wicri:level="3"><nlm:affiliation>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Saussereau, Elodie" sort="Saussereau, Elodie" uniqKey="Saussereau E" first="Elodie" last="Saussereau">Elodie Saussereau</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Le Havre</settlement></placeName></affiliation></author><author><name sortKey="Goulle, Jean Pierre" sort="Goulle, Jean Pierre" uniqKey="Goulle J" first="Jean-Pierre" last="Goullé">Jean-Pierre Goullé</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Le Havre</settlement></placeName></affiliation></author><author><name sortKey="Castanet, Mireille" sort="Castanet, Mireille" uniqKey="Castanet M" first="Mireille" last="Castanet">Mireille Castanet</name><affiliation wicri:level="3"><nlm:affiliation>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author></analytic><series><title level="j">Pharmacology research & perspectives</title><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In France, it has become the leading antiemetic mediator due to its good tolerance, however, its pharmacokinetics has never previously been studied in children. MPZ was administered by oral route to 8 children with a single dose of 0.33 mg/kg during an endocrine exploration using stimuli well known for its adverse emetic effects. We used biological remnants from sera following an hGH test in order to obtain the MPZ pharmacokinetics. Plasmatic concentrations of MPZ and the active acid metabolite AMPZ, were quantified by HPLC-MS/MS during a 270 min test period. MPZ is quickly absorbed with a median C max of 17.2 ng/mL at one hour and its half-life is 2.18 h. The plasmatic concentrations of AMPZ were higher than MPZ with a median C max of 76.3 ng/mL, a T max to 150 min and its concentration was approximately maintained at 50 ng/mL from 1 to 4 h. The plasmatic concentrations in children are similar to those observed in adults. No adverse effects, nausea or vomiting occurred during the trial. Therefore, these results confirm the MPZ dosage that should be used in children under 15 kg administered as 0.33 mg/kg up to 3 times a day.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">26171218</PMID><DateCreated><Year>2015</Year><Month>7</Month><Day>14</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>7</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Pharmacology research & perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic study of metopimazine by oral route in children.</ArticleTitle><Pagination><MedlinePgn>e00130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.130</ELocationID><Abstract><AbstractText>Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In France, it has become the leading antiemetic mediator due to its good tolerance, however, its pharmacokinetics has never previously been studied in children. MPZ was administered by oral route to 8 children with a single dose of 0.33 mg/kg during an endocrine exploration using stimuli well known for its adverse emetic effects. We used biological remnants from sera following an hGH test in order to obtain the MPZ pharmacokinetics. Plasmatic concentrations of MPZ and the active acid metabolite AMPZ, were quantified by HPLC-MS/MS during a 270 min test period. MPZ is quickly absorbed with a median C max of 17.2 ng/mL at one hour and its half-life is 2.18 h. The plasmatic concentrations of AMPZ were higher than MPZ with a median C max of 76.3 ng/mL, a T max to 150 min and its concentration was approximately maintained at 50 ng/mL from 1 to 4 h. The plasmatic concentrations in children are similar to those observed in adults. No adverse effects, nausea or vomiting occurred during the trial. Therefore, these results confirm the MPZ dosage that should be used in children under 15 kg administered as 0.33 mg/kg up to 3 times a day.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mallet</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bounoure</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skiba</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutics Laboratory (UMR CNRS 5007), Faculty of Medicine and Pharmacy, Rouen University 76183, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saussereau</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goullé</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Laboratoire de pharmacocinétique et de toxicologie cliniques, Groupe Hospitalier du Havre BP 24, 76083, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanet</LastName><ForeName>Mireille</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ENG</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>Jun</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><OtherID Source="NLM">PMC4492748</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiemetic drug</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">metopimazine</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26171218</ArticleId><ArticleId IdType="doi">10.1002/prp2.130</ArticleId><ArticleId IdType="pmc">PMC4492748</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Haute-Normandie</li><li>Région Normandie</li></region><settlement><li>Le Havre</li><li>Rouen</li></settlement></list><tree><country name="France"><region name="Région Normandie"><name sortKey="Mallet, Eric" sort="Mallet, Eric" uniqKey="Mallet E" first="Eric" last="Mallet">Eric Mallet</name></region><name sortKey="Bounoure, Frederic" sort="Bounoure, Frederic" uniqKey="Bounoure F" first="Frederic" last="Bounoure">Frederic Bounoure</name><name sortKey="Castanet, Mireille" sort="Castanet, Mireille" uniqKey="Castanet M" first="Mireille" last="Castanet">Mireille Castanet</name><name sortKey="Goulle, Jean Pierre" sort="Goulle, Jean Pierre" uniqKey="Goulle J" first="Jean-Pierre" last="Goullé">Jean-Pierre Goullé</name><name sortKey="Saussereau, Elodie" sort="Saussereau, Elodie" uniqKey="Saussereau E" first="Elodie" last="Saussereau">Elodie Saussereau</name><name sortKey="Skiba, Mohamed" sort="Skiba, Mohamed" uniqKey="Skiba M" first="Mohamed" last="Skiba">Mohamed Skiba</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000080 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000080 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26171218
|texte= Pharmacokinetic study of metopimazine by oral route in children.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26171218" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LeHavreV1
| This area was generated with Dilib version V0.6.25. |  |